Annual D&A
$181.30 M
+$33.00 M+22.25%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual depreciation & amortization is currently $181.30 million, with the most recent change of +$33.00 million (+22.25%) on 31 December 2023. During the last 3 years, it has risen by +$71.80 million (+65.57%). VRTX annual D&A is now at all-time high.VRTX Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$53.20 M
-$800.00 K-1.48%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly depreciation & amortization is currently $53.20 million, with the most recent change of -$800.00 thousand (-1.48%) on 30 September 2024. Over the past year, it has increased by +$11.10 million (+26.37%). VRTX quarterly D&A is now -9.83% below its all-time high of $59.00 million, reached on 31 December 2023.VRTX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$219.70 M
+$11.10 M+5.32%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM depreciation & amortization is currently $219.70 million, with the most recent change of +$11.10 million (+5.32%) on 30 September 2024. Over the past year, it has increased by +$59.00 million (+36.71%). VRTX TTM D&A is now at all-time high.VRTX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.3% | +26.4% | +36.7% |
| 3 y3 years | +65.6% | +67.8% | +81.4% |
| 5 y5 years | +150.3% | +105.8% | +120.8% |
VRTX Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +65.6% | -9.8% | +67.8% | at high | +81.4% |
| 5 y | 5 years | at high | +150.3% | -9.8% | +105.8% | at high | +120.8% |
| alltime | all time | at high | +9972.2% | -9.8% | +8766.7% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $53.20 M(-1.5%) | $219.70 M(+5.3%) |
| June 2024 | - | $54.00 M(+0.9%) | $208.60 M(+6.4%) |
| Mar 2024 | - | $53.50 M(-9.3%) | $196.00 M(+8.1%) |
| Dec 2023 | $181.30 M(+22.3%) | $59.00 M(+40.1%) | $181.30 M(+12.8%) |
| Sept 2023 | - | $42.10 M(+1.7%) | $160.70 M(+3.5%) |
| June 2023 | - | $41.40 M(+6.7%) | $155.30 M(+2.7%) |
| Mar 2023 | - | $38.80 M(+1.0%) | $151.20 M(+2.0%) |
| Dec 2022 | $148.30 M(+18.1%) | $38.40 M(+4.6%) | $148.30 M(+3.2%) |
| Sept 2022 | - | $36.70 M(-1.6%) | $143.70 M(+3.6%) |
| June 2022 | - | $37.30 M(+3.9%) | $138.70 M(+4.5%) |
| Mar 2022 | - | $35.90 M(+6.2%) | $132.70 M(+5.7%) |
| Dec 2021 | $125.60 M(+14.7%) | $33.80 M(+6.6%) | $125.60 M(+3.7%) |
| Sept 2021 | - | $31.70 M(+1.3%) | $121.14 M(+4.4%) |
| June 2021 | - | $31.30 M(+8.7%) | $116.08 M(+4.1%) |
| Mar 2021 | - | $28.80 M(-1.8%) | $111.48 M(+1.8%) |
| Dec 2020 | $109.50 M(+2.4%) | $29.34 M(+10.1%) | $109.50 M(+2.9%) |
| Sept 2020 | - | $26.64 M(-0.2%) | $106.38 M(+0.8%) |
| June 2020 | - | $26.70 M(-0.5%) | $105.58 M(-0.9%) |
| Mar 2020 | - | $26.82 M(+2.3%) | $106.58 M(-0.3%) |
| Dec 2019 | $106.90 M(+47.6%) | $26.21 M(+1.4%) | $106.90 M(+7.4%) |
| Sept 2019 | - | $25.85 M(-6.7%) | $99.51 M(+7.2%) |
| June 2019 | - | $27.70 M(+2.1%) | $92.86 M(+11.6%) |
| Mar 2019 | - | $27.14 M(+44.2%) | $83.22 M(+14.9%) |
| Dec 2018 | $72.42 M(+18.0%) | $18.83 M(-1.9%) | $72.42 M(+3.4%) |
| Sept 2018 | - | $19.19 M(+6.3%) | $70.03 M(+6.0%) |
| June 2018 | - | $18.06 M(+10.5%) | $66.06 M(+5.0%) |
| Mar 2018 | - | $16.34 M(-0.5%) | $62.89 M(+2.4%) |
| Dec 2017 | $61.40 M(-0.0%) | $16.43 M(+7.9%) | $61.40 M(+1.6%) |
| Sept 2017 | - | $15.22 M(+2.2%) | $60.42 M(+1.1%) |
| June 2017 | - | $14.89 M(+0.3%) | $59.76 M(-0.1%) |
| Mar 2017 | - | $14.85 M(-3.9%) | $59.83 M(-2.5%) |
| Dec 2016 | $61.40 M(-1.5%) | $15.45 M(+6.1%) | $61.40 M(-0.5%) |
| Sept 2016 | - | $14.57 M(-2.6%) | $61.69 M(-2.5%) |
| June 2016 | - | $14.96 M(-8.8%) | $63.29 M(+1.4%) |
| Mar 2016 | - | $16.41 M(+4.2%) | $62.40 M(+0.1%) |
| Dec 2015 | $62.34 M(-1.4%) | $15.75 M(-2.6%) | $62.34 M(-0.9%) |
| Sept 2015 | - | $16.17 M(+15.0%) | $62.93 M(-1.2%) |
| June 2015 | - | $14.06 M(-14.0%) | $63.73 M(-0.2%) |
| Mar 2015 | - | $16.36 M(+0.2%) | $63.83 M(+0.9%) |
| Dec 2014 | $63.26 M(+30.8%) | $16.34 M(-3.7%) | $63.26 M(-2.0%) |
| Sept 2014 | - | $16.96 M(+19.7%) | $64.55 M(+13.1%) |
| June 2014 | - | $14.17 M(-10.2%) | $57.08 M(+6.8%) |
| Mar 2014 | - | $15.79 M(-10.5%) | $53.46 M(+10.5%) |
| Dec 2013 | $48.37 M(+26.6%) | $17.63 M(+85.8%) | $48.37 M(+12.2%) |
| Sept 2013 | - | $9.49 M(-10.1%) | $43.11 M(+2.1%) |
| June 2013 | - | $10.55 M(-1.3%) | $42.21 M(+4.7%) |
| Mar 2013 | - | $10.69 M(-13.6%) | $40.32 M(+5.6%) |
| Dec 2012 | $38.19 M(+9.0%) | $12.37 M(+44.0%) | $38.19 M(+7.5%) |
| Sept 2012 | - | $8.59 M(-0.8%) | $35.54 M(+2.4%) |
| June 2012 | - | $8.66 M(+1.2%) | $34.70 M(-0.1%) |
| Mar 2012 | - | $8.56 M(-12.0%) | $34.74 M(-0.9%) |
| Dec 2011 | $35.04 M(+15.0%) | $9.72 M(+25.5%) | $35.04 M(+4.5%) |
| Sept 2011 | - | $7.75 M(-11.0%) | $33.52 M(+3.0%) |
| June 2011 | - | $8.71 M(-1.7%) | $32.53 M(+2.5%) |
| Mar 2011 | - | $8.86 M(+8.0%) | $31.73 M(+4.2%) |
| Dec 2010 | $30.46 M(+1.2%) | $8.21 M(+21.4%) | $30.46 M(-0.6%) |
| Sept 2010 | - | $6.76 M(-14.6%) | $30.64 M(-0.2%) |
| June 2010 | - | $7.91 M(+4.3%) | $30.69 M(+0.5%) |
| Mar 2010 | - | $7.58 M(-9.5%) | $30.53 M(+1.4%) |
| Dec 2009 | $30.11 M(-6.5%) | $8.38 M(+23.0%) | $30.11 M(-0.6%) |
| Sept 2009 | - | $6.82 M(-12.0%) | $30.30 M(-3.6%) |
| June 2009 | - | $7.75 M(+8.1%) | $31.44 M(-1.3%) |
| Mar 2009 | - | $7.16 M(-16.5%) | $31.86 M(-1.0%) |
| Dec 2008 | $32.20 M | $8.57 M(+7.8%) | $32.20 M(+3.6%) |
| Sept 2008 | - | $7.95 M(-2.7%) | $31.07 M(+3.7%) |
| June 2008 | - | $8.17 M(+9.0%) | $29.95 M(+4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $7.50 M(+0.6%) | $28.64 M(+4.3%) |
| Dec 2007 | $27.46 M(+6.2%) | $7.45 M(+9.0%) | $27.46 M(+2.1%) |
| Sept 2007 | - | $6.83 M(-0.2%) | $26.88 M(+3.5%) |
| June 2007 | - | $6.85 M(+8.4%) | $25.98 M(+0.2%) |
| Mar 2007 | - | $6.32 M(-8.1%) | $25.94 M(+0.3%) |
| Dec 2006 | $25.87 M(-5.2%) | $6.88 M(+15.9%) | $25.87 M(-0.1%) |
| Sept 2006 | - | $5.93 M(-12.9%) | $25.88 M(-4.1%) |
| June 2006 | - | $6.81 M(+8.9%) | $26.98 M(+1.0%) |
| Mar 2006 | - | $6.25 M(-9.3%) | $26.70 M(-2.2%) |
| Dec 2005 | $27.29 M(-7.9%) | $6.89 M(-2.0%) | $27.29 M(-4.0%) |
| Sept 2005 | - | $7.03 M(+7.6%) | $28.42 M(-0.6%) |
| June 2005 | - | $6.53 M(-4.5%) | $28.60 M(-2.6%) |
| Mar 2005 | - | $6.84 M(-14.7%) | $29.36 M(-1.0%) |
| Dec 2004 | $29.64 M(+26.5%) | $8.02 M(+11.3%) | $29.64 M(+6.8%) |
| Sept 2004 | - | $7.21 M(-1.0%) | $27.74 M(+19.9%) |
| June 2004 | - | $7.28 M(+2.2%) | $23.14 M(-0.8%) |
| Mar 2004 | - | $7.13 M(+16.3%) | $23.31 M(-0.5%) |
| Dec 2003 | $23.44 M(-5.9%) | $6.12 M(+135.3%) | $23.44 M(-2.7%) |
| Sept 2003 | - | $2.60 M(-65.1%) | $24.08 M(-14.1%) |
| June 2003 | - | $7.46 M(+2.9%) | $28.05 M(+4.4%) |
| Mar 2003 | - | $7.25 M(+7.1%) | $26.87 M(+7.9%) |
| Dec 2002 | $24.91 M(+38.6%) | $6.77 M(+3.0%) | $24.91 M(+4.4%) |
| Sept 2002 | - | $6.57 M(+4.6%) | $23.86 M(-0.4%) |
| June 2002 | - | $6.28 M(+18.9%) | $23.95 M(+15.5%) |
| Mar 2002 | - | $5.28 M(-7.7%) | $20.72 M(+15.4%) |
| Dec 2001 | $17.96 M(+40.4%) | $5.72 M(-14.0%) | $17.96 M(-3.6%) |
| Sept 2001 | - | $6.66 M(+117.7%) | $18.63 M(+30.4%) |
| June 2001 | - | $3.06 M(+21.2%) | $14.29 M(+7.1%) |
| Mar 2001 | - | $2.52 M(-60.5%) | $13.34 M(+4.3%) |
| Dec 2000 | $12.79 M(+103.0%) | $6.39 M(+176.3%) | $12.79 M(+52.3%) |
| Sept 2000 | - | $2.31 M(+9.7%) | $8.40 M(+8.9%) |
| June 2000 | - | $2.11 M(+6.8%) | $7.71 M(+9.0%) |
| Mar 2000 | - | $1.98 M(-1.3%) | $7.08 M(+12.3%) |
| Dec 1999 | $6.30 M(+37.0%) | $2.00 M(+23.1%) | $6.30 M(+8.6%) |
| Sept 1999 | - | $1.63 M(+10.2%) | $5.80 M(+10.0%) |
| June 1999 | - | $1.48 M(+22.9%) | $5.28 M(+7.7%) |
| Mar 1999 | - | $1.20 M(-20.0%) | $4.90 M(+6.5%) |
| Dec 1998 | $4.60 M(+27.8%) | $1.50 M(+36.4%) | $4.60 M(+12.2%) |
| Sept 1998 | - | $1.10 M(0.0%) | $4.10 M(+2.5%) |
| June 1998 | - | $1.10 M(+22.2%) | $4.00 M(+8.1%) |
| Mar 1998 | - | $900.00 K(-10.0%) | $3.70 M(+2.8%) |
| Dec 1997 | $3.60 M(+12.5%) | $1.00 M(0.0%) | $3.60 M(+9.1%) |
| Sept 1997 | - | $1.00 M(+25.0%) | $3.30 M(+6.5%) |
| June 1997 | - | $800.00 K(0.0%) | $3.10 M(-3.1%) |
| Mar 1997 | - | $800.00 K(+14.3%) | $3.20 M(0.0%) |
| Dec 1996 | $3.20 M(-13.5%) | $700.00 K(-12.5%) | $3.20 M(-8.6%) |
| Sept 1996 | - | $800.00 K(-11.1%) | $3.50 M(-5.4%) |
| June 1996 | - | $900.00 K(+12.5%) | $3.70 M(+5.7%) |
| Mar 1996 | - | $800.00 K(-20.0%) | $3.50 M(-5.4%) |
| Dec 1995 | $3.70 M(+5.7%) | $1.00 M(0.0%) | $3.70 M(0.0%) |
| Sept 1995 | - | $1.00 M(+42.9%) | $3.70 M(+8.8%) |
| June 1995 | - | $700.00 K(-30.0%) | $3.40 M(-5.6%) |
| Mar 1995 | - | $1.00 M(0.0%) | $3.60 M(+2.9%) |
| Dec 1994 | $3.50 M(-10.3%) | $1.00 M(+42.9%) | $3.50 M(-2.8%) |
| Sept 1994 | - | $700.00 K(-22.2%) | $3.60 M(-5.3%) |
| June 1994 | - | $900.00 K(0.0%) | $3.80 M(-5.0%) |
| Mar 1994 | - | $900.00 K(-18.2%) | $4.00 M(+2.6%) |
| Dec 1993 | $3.90 M(+39.3%) | $1.10 M(+22.2%) | $3.90 M(+11.4%) |
| Sept 1993 | - | $900.00 K(-18.2%) | $3.50 M(+6.1%) |
| June 1993 | - | $1.10 M(+37.5%) | $3.30 M(+10.0%) |
| Mar 1993 | - | $800.00 K(+14.3%) | $3.00 M(+7.1%) |
| Dec 1992 | $2.80 M(+55.6%) | $700.00 K(0.0%) | $2.80 M(+33.3%) |
| Sept 1992 | - | $700.00 K(-12.5%) | $2.10 M(+50.0%) |
| June 1992 | - | $800.00 K(+33.3%) | $1.40 M(+133.3%) |
| Mar 1992 | - | $600.00 K | $600.00 K |
| Dec 1991 | $1.80 M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual depreciation & amortization?
- What is the all time high annual D&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual D&A year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly D&A year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM depreciation & amortization?
- What is the all time high TTM D&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM D&A year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual depreciation & amortization?
The current annual D&A of VRTX is $181.30 M
What is the all time high annual D&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual depreciation & amortization is $181.30 M
What is Vertex Pharmaceuticals Incorporated annual D&A year-on-year change?
Over the past year, VRTX annual depreciation & amortization has changed by +$33.00 M (+22.25%)
What is Vertex Pharmaceuticals Incorporated quarterly depreciation & amortization?
The current quarterly D&A of VRTX is $53.20 M
What is the all time high quarterly D&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly depreciation & amortization is $59.00 M
What is Vertex Pharmaceuticals Incorporated quarterly D&A year-on-year change?
Over the past year, VRTX quarterly depreciation & amortization has changed by +$11.10 M (+26.37%)
What is Vertex Pharmaceuticals Incorporated TTM depreciation & amortization?
The current TTM D&A of VRTX is $219.70 M
What is the all time high TTM D&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM depreciation & amortization is $219.70 M
What is Vertex Pharmaceuticals Incorporated TTM D&A year-on-year change?
Over the past year, VRTX TTM depreciation & amortization has changed by +$59.00 M (+36.71%)